Welcome to our dedicated page for Aligos Therapeutics SEC filings (Ticker: ALGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aligos Therapeutics Inc (ALGS) files regulatory documents with the SEC that detail the company's clinical development activities, financial position, and operational risks inherent in biopharmaceutical drug development. For a clinical-stage biotech company, these filings provide critical insight into trial progress, cash runway, and partnership strategies that aren't always apparent from press releases.
The company's 10-K annual reports and 10-Q quarterly filings detail clinical trial designs, enrollment status, and development timelines for multiple hepatitis B drug candidates. These documents explain the scientific rationale behind different therapeutic approaches—oligonucleotides, capsid assembly modulators, and siRNA therapies—and outline the regulatory pathway for each program. Financial statements reveal how capital is allocated across programs, helping investors understand which candidates receive priority funding.
Form 4 insider transaction filings show when executives and directors buy or sell shares, potentially signaling confidence levels ahead of data readouts or other material events. 8-K current report filings announce material events such as clinical trial initiations, data presentations, partnership agreements, or changes in leadership. Our AI-powered summaries explain complex clinical endpoints and regulatory terminology, translating scientific language into accessible insights.
For biotech investors, understanding SEC filings helps assess whether the company has sufficient capital to complete ongoing trials, how management discusses clinical risks, and what contingency plans exist if trials don't meet endpoints. These documents provide the detailed context behind headline announcements, revealing the strategic thinking and financial constraints shaping development decisions.
Aligos Therapeutics (ALGS) filed its quarterly report for the period ended September 30, 2025. The company reported a Q3 net loss of
Liquidity improved after a February 2025 PIPE that generated gross proceeds of
As of October 31, 2025, shares outstanding were 6,153,582, comprised of 5,353,582 voting and 800,000 non‑voting shares. There were 4,217,432 pre‑funded warrants outstanding as of October 31, 2025 that are immediately exercisable, subject to beneficial ownership limitations.
Aligos Therapeutics (ALGS)8-K under Item 2.02 (Results of Operations and Financial Condition) on November 6, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference in the report.
The company states the information under Item 2.02 and Exhibit 99.1 is being furnished and not deemed filed for purposes of Section 18 of the Exchange Act, and it will not be incorporated into other filings unless expressly referenced. Aligos’ common stock trades on the Nasdaq Capital Market under the symbol ALGS.
Woodline Partners LP, as investment adviser to Woodline Master Fund LP, reports beneficial ownership of 518,300 shares of Aligos Therapeutics Voting Common Stock, representing 9.8% of the class based on 5,314,801 shares outstanding. The Schedule 13G/A shows Woodline holds sole voting and sole dispositive power over the reported shares. The filing includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. This disclosure notifies the market of a near-10% passive stake in ALGS.
This Schedule 13G discloses that Sio Capital Management, LLC beneficially owned 355,937 shares of Aligos Therapeutics common stock, representing 5.49% of the class. The filing states these shares are held by affiliated funds for which Sio acts as a registered investment adviser, and that Sio has shared voting and shared dispositive power over the reported shares while having no sole voting or dispositive power. The percentage is calculated using 6,114,801 shares outstanding as reported in the issuer's 10-Q. Item 10 certifies the position was acquired and is held in the ordinary course of business and not to influence control. The filing also notes that Sio and its GP are controlled by Michael Castor, though any beneficial ownership by the GP or Mr. Castor is expressly disclaimed.
Adage Capital Management, L.P., together with reporting persons Robert Atchinson and Phillip Gross, disclosed beneficial ownership of 210,000 shares of Aligos Therapeutics common stock, representing 3.90% of the outstanding class on the basis indicated in the filing. The position includes 70,000 shares issuable upon exercise of warrants. The filing shows no sole voting or dispositive power and reports the stake as held with shared voting and dispositive power. The certifying statement indicates the securities were acquired and are held in the ordinary course of business and not for the purpose of changing control.
Aligos Therapeutics (ALGS) Q2-25 Form 10-Q shows a capital-strengthening quarter driven by its February 2025 $105 million PIPE financing. Net proceeds of $101.4 million and the re-measurement of 2023 warrants (-$63.2 million liability) swung stockholders’ equity from a $(29.0) million deficit at 12/31/24 to $101.9 million at 6/30/25. Shares outstanding rose to 6.15 million (post 1-for-25 split).
Liquidity: Cash & cash equivalents fell to $18.7 million, but short-term U.S. Treasury holdings increased to $104.3 million, lifting total liquid resources to $122.9 million. Management states this provides >12-month runway.
Operations: The company remains pre-commercial. Customer revenue was $1.3 million YTD (-27% YoY) tied to Amoytop R&D services. Six-month R&D expense fell 24% YoY to $28.5 million; G&A dropped 19% to $10.6 million. Operating loss narrowed to $37.8 million (vs. $48.5 million). However, after the warrant fair-value gain and $2.1 million interest income, YTD net income reached $27.2 million (prior-year loss $29.8 million).
Cash flow: OCF was -$36.4 million; capex minimal. Financing inflow of $101.6 million (PIPE & ESPP) offset $83.5 million deployed into Treasuries.
- 2025 PIPE issued 2.10 million shares, 1.92 million pre-funded warrants and 2.01 million common warrants (exercise $26.02; expiry 2032).
- Authorized share cap raised to 100 million voting and 15.8 million non-voting shares.
- Phase 2 CAM-E candidate ALG-000184 B-SUPREME trial has begun enrollment; interim read-out expected 2026.
Outlook: Aligos projects current cash to fund ≥12 months of R&D. Future value hinges on clinical read-outs and additional financings; no commercial revenue is expected near term.
Aligos Therapeutics (ALGS) filed a routine Form 4 disclosing that director Carole Nuechterlein received a stock option grant for 5,860 common shares on 06/25/2025 at an exercise price of $7.63 per share. The option will vest 100% on the earlier of the first anniversary of the grant date or immediately prior to the company’s 2026 annual shareholders meeting, contingent upon her continued board service.
No shares were bought or sold and no other material transactions or changes in beneficial ownership were reported.
Aligos Therapeutics (NASDAQ:ALGS) submitted a routine Form 4 detailing an equity award to director James P. Scopa. On 25-Jun-2025 he received a stock option grant for 5,860 shares at an exercise price of $7.63 per share. The option vests 100% on the earlier of the first anniversary of the grant date or immediately before the company’s 2026 annual meeting and carries an expiration date of 25-Jun-2035. Following the transaction the director beneficially owns 5,860 derivative securities. No common shares were sold or otherwise disposed of, and the filing does not indicate any change in the company’s financial condition or strategy.
FAQ
What is the current stock price of Aligos Therapeutics (ALGS)?
What is the market cap of Aligos Therapeutics (ALGS)?
